Cancer therapy-induced hyponatremia: A case-illustrated review

Hyponatremia is the most common electrolyte disorder in patients with cancer and associated significant morbidity mortality. Innovation therapies has led to substantial improvement outcomes, but also new therapy-related toxicities, including disturbance. Improvement clinicians understanding of hyponatremia may mitigate adverse outcomes improve quality life patients. In this case-illustrated review, we discuss mechanisms underlying drug-induced both “classical” antineoplastic drugs novel therapies. Via these clinical cases, describe caused by conventional chemotherapies (e.g. platinum compounds, vinca alkaloid, alkylating agents) as well related tyrosine kinase inhibitors other targeted We focus on checkpoint inhibitors-induced hyponatremia, agents are increasingly used for a wide variety malignancies. Lastly, summarize among recipients newer treatments multiple myeloma.